Dose Modifications in Exposure-Response Analyses of Oncology Drug Development: Brigimadlin Case Study

Oncology

PBPK & PBBM

MIDD

Pharmacometrics

Methodology

ACoP16 (Oct 2025), Poster: M-115

Le Louedec F, Kang J, Sarr C, Neldemo I, Wiens M, Baron K, Lamar M, Pérez-Pitarch A, Schmid U, Sailer R, Bergstrand M, Busse D